Seladelpar 10 mg + Placebo + Seladelpar 5 mg
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Biliary Cholangitis
Conditions
Primary Biliary Cholangitis
Trial Timeline
Apr 21, 2021 → Aug 11, 2023
NCT ID
NCT04620733About Seladelpar 10 mg + Placebo + Seladelpar 5 mg
Seladelpar 10 mg + Placebo + Seladelpar 5 mg is a phase 3 stage product being developed by Gilead Sciences for Primary Biliary Cholangitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04620733. Target conditions include Primary Biliary Cholangitis.
What happened to similar drugs?
20 of 20 similar drugs in Primary Biliary Cholangitis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04620733 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Biliary Cholangitis